Furthermore, GLP-1-Fc-FGF21 D1 also offered more significant therapeutic effects in attenuating NASH progression regarding hepatic function, lipid profiles, and NAS scores than the single agonists. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.